IN THE CLAIMS

Claim 1 (currently amended): A compound of formula (I)



(I)

wherein:

A is a 5- or 6-membered monocyclic aromatic ring containing 1, 2 or 3 ring heteroatoms selected from nitrogen, oxygen and sulphur atoms and is unsubstituted or is substituted by one, two or three atoms or groups selected from halo, oxo, carboxy, trifluoromethyl, cyano, amino, hydroxy, nitro, C_{1-4}alkyl, C_{1-4}alkoxy, C_{1-4}alkoxycarbonyl, C_{1-4}alkylamino, di-C_{1-4}alkylamino or aminoC_{1-4}alkyl;

~~the 1,4-phenylene ring of a compound of formula (I) is either unsubstituted or is substituted by one or two substituents selected from halo, trifluoromethyl, trifluoromethoxy, cyano, nitro,~~

~~C_{1-4}alkyl, C_{2-4}alkenyl and C_{2-4}alkynyl, from the substituent $-(CH_2)_n-Y^1$ wherein n is 0-4 and Y^1 is selected from hydroxy, amino, carboxy, C_{1-4}alkoxy, C_{2-4}alkenyloxy, C_{2-4}alkynyloxy, C_{1-4}alkylamino, di-C_{1-4}alkylamino, pyrrolidin-1-yl, piperidino, morpholino, thiomorpholino, 1-oxothiomorpholino, 1,1-dioxothiomorpholino, piperazin-1-yl, 4-C_{1-4}alkylpiperazin-1-yl, C_{1-4}alkylthio, C_{1-4}alkylsulphinyl, C_{1-4}alkylsulphonyl, C_{2-4}alkanoylamino, benzamido, C_{1-4}alkylsulphonamido and phenylsulphonamido, from the substituent $-(CH_2)_n-Y^2$ wherein n is 0-4 and Y^2 is selected from carboxy, carbamoyl, C_{1-4}alkoxycarbonyl, N-C_{1-4}alkylcarbamoyl, N,N-di-C_{1-4}alkylcarbamoyl, pyrrolidin-1-ylcarbonyl, piperidinocarbonyl, morpholinocarbonyl, thiomorpholinocarbonyl, 1-oxothiomorpholinocarbonyl, 1,1-dioxothiomorpholinocarbonyl, piperazin-1-ylcarbonyl, 4-C_{1-4}alkylpiperazin-1-ylcarbonyl, C_{1-4}alkylsulphonamidocarbonyl, phenylsulphonamidocarbonyl and benzylsulphonamidocarbonyl, from a substituent of the formula $-X^3-L^2-Y^2$ wherein X^3 is a group of the formula $CON(R^5)$, $CON(L^2-Y^2)$, $C(R^5)_2O$, O, $N(R^5)$ or $N(L^2-Y^2)$, L^2 is~~

~~C_{1-4}alkylene, Y^2 has any of the meanings defined immediately hereinbefore and each R^5 is independently hydrogen or C_{1-4}alkyl, and from a substituent of the formula X^3-L^3-Y^1 wherein X^3 is a group of the formula CON(R^5), CON(L^3-Y^1), C(R^5)$_2$O, O, N(R^5) or N(L^3-Y^1), L^3 is C_{2-4}alkylene, Y^1 has any of the meanings defined immediately hereinbefore and each R^5 is independently hydrogen or C_{1-4}alkyl, and wherein any heterocyclic group in a substituent of the 1,4-phenylene ring of compounds of formula (I) optionally bears 1 or 2 substituents selected from carboxy, carbamoyl, C_{1-4}alkyl, C_{1-4}alkoxycarbonyl, N-C_{1-4}alkylcarbamoyl and N,N-di-C_{1-4}alkylcarbamoyl, and wherein any phenyl group in a substituent of the 1,4-phenylene ring of compounds of formula (I) optionally bears 1 or 2 substituents selected from halo, trifluoromethyl, cyano, C_{1-4}alkyl, C_{2-4}alkenyl, C_{2-4}alkynyl, C_{1-4}alkoxy, C_{2-4}alkenyloxy and C_{2-4}alkynyloxy;~~

B is ~~CH or~~ N; and

~~the heterocyclic ring containing B is either unsubstituted or is substituted by one or two substituents selected from hydroxy, oxo, carboxy and C_{1-4}alkoxycarbonyl; or one of the following:~~

~~-$(CH_2)_n$-R, -$(CH_2)_n$-NRR^1, -CO-R, -CO-NRR^1, -$(CH_2)_n$-CO-R and -$(CH_2)_n$-CO-NRR^1;~~

~~wherein n is 0, 1 or 2, preferably n is 1 or 2;~~

~~R and R^1 are independently selected from hydrogen, C_{1-4}alkyl, C_{2-4}alkenyl, C_{2-4}alkynyl, hydroxyC_{1-4}alkyl, carboxyC_{1-4}alkyl and C_{1-4}alkoxycarbonylC_{1-4}alkyl or where possible R and R^1 may together form a 5- or 6-membered optionally substituted saturated or partially unsaturated heterocyclic ring which may include in addition to the nitrogen to which R and R^1 are attached 1 or 2 additional heteroatoms selected from nitrogen, oxygen and sulphur;~~

D is 2-indolyl~~, 2-benzimidazolyl, 2-benzo[b]furanyl, 2-pyrrolo[2,3-b]pyridyl, 2-furo[2,3-b]pyridyl or 6-7H-cyclopenta[b]pyridyl and is unsubstituted or is substituted by one, two or three substituents selected from halo, trifluromethyl, trifluoromethoxy, cyano, hydroxy, oxo, amino, nitro, trifluoromethylsulphonyl, carboxy, carbamoyl, C_{1-4}alkyl, C_{2-4}alkenyl, C_{2-4}alkynyl, C_{1-4}alkoxy, C_{2-4}alkenyloxy, C_{2-4}alkynyloxy, C_{1-4}alkylthio, C_{1-4}alkylsulphinyl, C_{1-4}alkylsulphonyl, C_{1-4}alkylamino, di-C_{1-4}alkylamino, C_{1-4}alkoxycarbonyl,~~

~~N-C$_{1-4}$alkylcarbamoyl, N,N-di-C$_{1-4}$alkylcarbamoyl, C$_{2-4}$alkanoyl, C$_{2-4}$alkanoylamino, hydroxyC$_{1-4}$alkyl, C$_{1-4}$alkoxyC$_{1-4}$alkyl, carboxyC$_{1-4}$alkyl, C$_{1-4}$alkoxycarbonylC$_{1-4}$alkyl, carbamoylC$_{1-4}$alkyl, N-C$_{1-4}$alkylcarbamoylC$_{1-4}$alkyl, N,N-di-C$_{1-4}$alkylcarbamoylC$_{1-4}$alkyl, phenyl, heteroaryl, phenoxy, phenylthio, phenylsulphinyl, phenylsulphonyl, benzyl, benzoyl, heteroaryloxy, heteroarylthio, heteroarylsulphinyl and heteroarylsulphonyl, and wherein said heteroaryl substituent or the heteroaryl group in a heteroaryl-containing substituent is a 5- or 6-membered monocyclic heteroaryl ring containing up to 3 heteroatoms selected from nitrogen, oxygen and sulphur, and wherein said phenyl, heteroaryl, phenoxy, phenylthio, phenylsulphinyl, phenylsulphonyl, heteroaryloxy, heteroarylthio, heteroarylsulphinyl, heteroarylsulphonyl, benzyl or benzoyl substituent optionally bears 1, 2 or 3 substituents selected from halo, trifluoromethyl, cyano, hydroxy, amino, nitro, carboxy, carbamoyl, C$_{1-4}$alkyl, C$_{1-4}$alkoxy, C$_{1-4}$alkylamino, di-C$_{1-4}$alkylamino, C$_{1-4}$alkoxycarbonyl, N-C$_{1-4}$alkylcarbamoyl, N,N-di-C$_{1-4}$alkylcarbamoyl and C$_{2-4}$alkanoylamino; and excluding the compound 1-(5-chlorobenzofuran-2-ylsulphonyl)-4-[4-(4-pyridyl)benzoyl] piperazine~~;
~~and~~ or a pharmaceutically-acceptable salt ~~salts~~ thereof.

Claim 2 (currently amended): A compound of formula (I) as claimed in claim 1 wherein A is a pyridyl, pyrimidinyl, imidazolyl or pyridazinyl ring;
or a pharmaceutically-acceptable salt thereof.

Claim 3 (currently amended): A compound of formula (I) as claimed in claim 2 wherein A is 2-pyridyl, 3-pyridyl, 4-pyridyl 3-pyradazinyl, 4-pyridazinyl, 4-pyrimidinyl, 5-pyrimidinyl, 1-imidazolyl, 2-imidazolyl or 4-imidazolyl;
or a pharmaceutically-acceptable salt thereof.

Claim 4 (currently amended): A compound of formula (I) as claimed in ~~any~~ claim ~~from~~ 1 ~~to 3~~ wherein A is substituted by C$_{1-4}$alkyl, amino and halo;
or a pharmaceutically-acceptable salt thereof.

Claim 5 (currently amended): A compound of formula (I) as claimed in ~~any~~ claim ~~from~~ 1 ~~to 3~~ wherein A is unsubstituted;
or a pharmaceutically-acceptable salt thereof.

Claims 6-10 (cancelled).

Claim 11 (currently amended): A compound of formula (I) as claimed in ~~any~~ claim ~~from~~ 1 ~~to 9~~ wherein D is substituted by bromo or chloro;
or a pharmaceutically-acceptable salt thereof.

Claim 12 (currently amended): A compound of formula (I) as claimed in claim 1 wherein:
A is pyridyl, pyrimidinyl, imidazolyl or pyridazinyl;
B is N;
D is 2-indolyl ~~or 2-benzo[b]furanyl both~~ optionally substituted by fluoro, chloro or bromo;
~~and~~ or a pharmaceutically-acceptable salt ~~salts~~ thereof.

Claim 13 (currently amended): 1-(5-Chloroindol-2-ylsulphonyl)-4-[4-(4-pyridyl)benzoyl] piperazine or a pharmaceutically-acceptable salt ~~salts~~ thereof.

Claim 14 (currently amended): 1-(5-Chloroindol-2-ylsulphonyl)-4-[4-(1-imidazolyl)benzoyl] piperazine or a pharmaceutically-acceptable salt ~~salts~~ thereof.

Claim 15 (cancelled).

Claim 16 (currently amended): A pharmaceutical composition comprising a compound of formula (I), or a pharmaceutically-acceptable salt thereof, as defined in any one of claims 1-5 or 11-14 ~~claim from 1 to 14~~, with a pharmaceutically-acceptable diluent or carrier.

Claim 17 (cancelled).

Claim 18 (currently amended): A method of treating a Factor Xa mediated disease or condition in a warm-blooded animal comprising administering an effective amount of a compound of formula (I), as defined in any one of claims 1-5 or 11-14 ~~claim from 1 to 14~~, or a pharmaceutically-acceptable salt thereof.